Global Giant Cell Arteritis Therapeutics Market size was valued at USD 1.14 Bn in 2024 and the total Giant Cell Arteritis Therapeutics Market revenue is expected to grow at 6% through 2025 to 2032, reaching nearly USD 1.82 Bn.Giant Cell Arteritis Therapeutics Market Introduction and Overview:
Giant Cell Arteritis (GCA) Therapeutics refer to medical treatment and pharmacological intervention used to manage giant cell arteritis, a chronic inflammatory disease affecting medium and large arteries particularly temporal arteries. The primary goals of GCA therapeutics are to reduce inflammation, prevent complication and achieve disease remission. Giant cell arteritis therapeutics market has been witnessing steady growth driven by increasing diagnosis rate and demand for targeted treatment in rheumatology and autoimmune care supported by stringent regulatory standard and rising geriatric population. North America dominated Giant cell arteritis therapeutics market fuelled by advanced healthcare infrastructure, high adoption of biologic therapies and key industry player like Roche (Actemra) and GlaxoSmithKline pioneering innovative treatment such as IL-6 inhibitors, corticosteroids and emerging JAK inhibitors.To Know About The Research Methodology :- Request Free Sample Report Giant cell arteritis therapeutics market benefit from diverse application with rheumatologist prioritizing early intervention to prevent vision loss and vascular complication while pharmaceutical companies integrate novel immunomodulator for long term remission. This evolving landscape highlight how Giant cell arteritis treatment are advancing with biologic innovation and precision medicine meeting modern demands for effective, steroid sparing therapies while aligning with broader healthcare goal of improved patient outcomes and reduced systemic side effect.
Giant Cell Arteritis Therapeutics Market Dynamics:
Awareness & Innovation to Boost Giant Cell Arteritis Therapeutics Market The rise in awareness and technological advancements in health care are encouraging people to opt for advanced and modern treatment procedures for treating giant cell arteritis. This is projected to fuel the growth of the global giant cell arteritis treatment market.Giant Cell Arteritis Therapeutics Market Segment Analysis:
Based on Therapeutics, Giant Cell Arteritis Therapeutics Market is segmented into Prednisone, Methotrexate, Tocilizumab, Aspirin and others. Tocilizumab therapeutics dominated the Giant Cell Arteritis Therapeutics Market with their efficiencies in treatment. Tocilizumab (TOC) is a humanized monoclonal antibody that blocks IL-6 signalling by binding to the alpha chain of the human IL-6 receptor. Genentech got FDA approval for a single-dose autoinjector filled with tocilizumab (Actemra) for patients with giant cell arteritis (GCA). Based on Mechanism of Action, Giant Cell Arteritis Therapeutics Market is segmented into Corticosteroids, Immunosuppressive Agents, Anticoagulants, etc. The corticosteroids segment dominated the Giant Cell Arteritis (GCA) therapeutics market by mechanism of action due to their irreplaceable role as first-line therapy, offering rapid and potent anti-inflammatory effects to prevent vision loss and vascular complications. As the gold-standard treatment per global guidelines, corticosteroids like prednisone are prescribed to nearly all GCA patients at diagnosis, ensuring widespread use. Their cost-effectiveness, immediate efficacy, and broad accessibility further solidify their dominance over emerging alternatives like IL-6 inhibitors (e.g., tocilizumab), which are primarily used as steroid-sparing agents rather than replacements. While biologics and immunosuppressants are gaining traction for long-term management, corticosteroids remain the cornerstone of acute-phase GCA treatment, maintaining the largest market share.
Giant Cell Arteritis Therapeutics Market Regional Insights:
North America accounted for the largest market share of xx% in 2024 and is expected to grow a CAGR of xx% in the forecast period. Growth in insurance coverage, presence of centers and institutes engaged in R&D and government funding are surging the North American market. Well-established healthcare infrastructure, ease of availability, and increasing immunization programs are also key drivers affecting the market growth. Investments by key players in this field have boosted the market growth. Europe is also expected to drive the market and the factors responsible for growth are the growing acceptance of emerging advanced technologies, rising incidence of GCA and tetanus.The Asia Pacific is also expected to witness significant growth during the forecast period due to rising health care expenditures. The allocation of a large amount of healthcare expenditure for hospitals and dispensing medicines to the elderly is expected to drive the market demand. Awareness programs by governments are also driving the market in the region.
Giant Cell Arteritis Therapeutics Market Competitive Landscape:
In the Giant Cell Arteritis (GCA) therapeutics market, Dr. Reddy’s Laboratories (India) operates as a strong generic and biosimilar player, competing with global leaders like Roche (tocilizumab/Actemra)—the dominant innovator with the only FDA-approved biologic for GCA—and GlaxoSmithKline (GSK), which explores novel immunosuppressants. Emerging innovators such as Kiniksa Pharmaceuticals (mavrilimumab) and Vifor Pharma are advancing targeted biologics and anti-inflammatory therapies, while Dr. Reddy’s leverages its expertise in cost-effective biosimilars (e.g., rituximab biosimilar) and steroid formulations to address affordability gaps in emerging markets. Though not a first-mover in GCA-specific drugs, Dr. Reddy’s positions itself as a key competitor in biosimilars and generic corticosteroids, challenging brands in price-sensitive regions while larger players focus on high-value biologics. The competitive landscape remains innovation-driven, with Roche leading, biologics expanding, and generics/biosimilars like Dr. Reddy’s capturing value in cost-conscious segments. Giant Cell Arteritis Therapeutics Market Key Trends: • Digital Biomarkers for Flare Prediction-Emerging AI-driven tools are analyzing patient-reported symptoms and wearable data to predict GCA flares before clinical onset, enabling preemptive treatment adjustments. • Epigenetic Therapies in Pipeline-Next-gen research is exploring drugs that modify gene expression linked to vascular inflammation, offering a potential long-term cure beyond immunosuppression. • Microbiome-Based Therapeutics-Early-stage studies suggest gut microbiome modulation could reduce systemic inflammation in GCA, opening a novel, non-immunosuppressive treatment avenue. Giant Cell Arteritis Therapeutics Market Key Developments: • Janssen Pharmaceuticals (US)-: May 15, 2024: Announced the initiation of a Phase II clinical trial (NCT06323496) for JNJ-77242113, an investigational oral IL-23 inhibitor, in patients with GCA. The study aims to evaluate its efficacy as a steroid-sparing therapy. • GlaxoSmithKline (UK)-October 10, 2024: Released positive topline results from its Phase III NIMBLE trial (NCT06112314) for belimumab in GCA, demonstrating a significant reduction in relapse rates compared to placebo. Full data was presented at the ACR Convergence 2024. • InflaRx (Germany)-June 5, 2025: Granted FDA Fast Track Designation for vilobelimab (IFX-1) in GCA following promising Phase II data showing reduced disease activity. A Phase III trial is expected to begin in Q4 2025. (Source: InflaRx Press Release, FDA Database) • Hisun Biopharmaceutical (China)-March 22, 2025: Received regulatory approval in China for its tocilizumab biosimilar (HS628) for GCA, marking the first biosimilar approval for the condition in Asia. (Source: NMPA Announcement, Hisun Corporate Filing) • Chugai Pharmaceutical (Japan)-January 30, 2025: Announced regulatory approval in Japan for subcutaneous Actemra (tocilizumab) for GCA, expanding treatment options beyond IV administration. (Source: Chugai News Release, PMDA Approval Docs)Giant Cell Arteritis Therapeutics Market Scope: Inquiry before Buying
Global Giant Cell Arteritis Therapeutics Market Report Coverage Details Base Year: 2024 Forecast Period: 2025-2032 Historical Data: 2019 to 2024 Market Size in 2024: USD 1.14 Bn. Forecast Period 2025 to 2032 CAGR: 6% Market Size in 2032: USD 1.82 Bn. Segments Covered: by Therapeutics Prednisone Methotrexate Tocilizumab Aspirin by Route of Administration Oral Intravenous Subcutaneous Others by Mechanism of Action Corticosteroids Immunosuppressive Agents Anticoagulants Others Giant Cell Arteritis Treatment Market, by Region
North America (United States, Canada, and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, ASEAN, Indonesia, Philippines, Malaysia, Vietnam, Thailand, ASEAN, Rest of Asia Pacific) Middle East & Africa (South Africa, GCC, Nigeria, Rest of ME&A) South America (Brazil, Argentina, Rest of South America)Giant Cell Arteritis Treatment Market, Key Players:
North America 1. Kiniksa Pharmaceuticals, Ltd. (US) 2. Regeneron (US) 3. AbbVie, Inc. (US) 4. Bristol-Myers Squibb Company (US) 5. Abbott (US) 6. Janssen Pharmaceuticals (US) 7. Pfizer Inc. (US) 8. Eli Lilly and Company (US) 9. ChemoCentryx (US) Europe 10. GlaxoSmithKline plc (UK) 11. InflaRx (Germany) 12. Fresenius Kabi Deutschland GmbH (Germany) 13. Sanofi (France) 14. AstraZeneca (Sweden) 15. F. Hoffmann-La Roche Ltd. (Switzerland) 16. Novartis AG (Switzerland) Asia Pacific 17. Bio Thera Solutions Ltd. (China) 18. Livzon Pharmaceutical Group Inc. (China) 19. Hisun Biopharmaceutical Co., Ltd. (China) 20. Chugai Pharmaceutical Co., Ltd. (Japan) 21. Dr Reddy’s Laboratories (India) 22. Celltrion, Inc. (South Korea)Frequently Asked Questions:
1. Which region has the largest share in Global Giant Cell Arteritis Treatment Market? Ans: North America region held the highest share in 2024. 2. What is the growth rate of Global Giant Cell Arteritis Treatment Market? Ans: The Global Giant Cell Arteritis Treatment Market is growing at a CAGR of 6% during forecasting period 2025-2032. 3. What is scope of the Global Giant Cell Arteritis Treatment Market report? Ans: Global Giant Cell Arteritis Treatment Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Giant Cell Arteritis Treatment Market? Ans: The important key players in the Global Giant Cell Arteritis Treatment Market are – Sanofi, Kiniksa Pharmaceuticals, Ltd., Regeneron, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Novartis AG, AbbVie, Inc., Bristol-Myers Squibb Company, Abbott, Johnson & Johnson Services, and Inc. 5. What is the study period of this Market? Ans: The Global Giant Cell Arteritis Treatment Market is studied from 2025 to 2032.
1. Giant Cell Arteritis Therapeutics Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Global Giant Cell Arteritis Therapeutics Market: Competitive Landscape 2.1. Ecosystem Analysis 2.2. MMR Competition Matrix 2.3. Competitive Landscape 2.4. Key Players Benchmarking 2.4.1. Company Name 2.4.2. Business Segment 2.4.3. Mechanism of Action Segment 2.4.4. Revenue (2024) 2.4.5. Company Locations 2.5. Market Structure 2.5.1. Market Leaders 2.5.2. Market Followers 2.5.3. Emerging Players 2.6. Mergers and Acquisitions Details 2.7. KANO Model Analysis 3. Giant Cell Arteritis Therapeutics Market: Dynamics 3.1. Giant Cell Arteritis Therapeutics Market Trends 3.1.1. North America Giant Cell Arteritis Therapeutics Market Trends 3.1.2. Europe Giant Cell Arteritis Therapeutics Market Trends 3.1.3. Asia Pacific Giant Cell Arteritis Therapeutics Market Trends 3.1.4. Middle East and Africa Giant Cell Arteritis Therapeutics Market Trends 3.1.5. South America Giant Cell Arteritis Therapeutics Market Trends 3.2. Global Giant Cell Arteritis Therapeutics Market Dynamics 3.2.1. Global Giant Cell Arteritis Therapeutics Market Drivers 3.2.1.1. Awareness & Innovation 3.2.2. Global Giant Cell Arteritis Therapeutics Market Restraints 3.2.3. Global Giant Cell Arteritis Therapeutics Market Opportunities 3.2.4. Global Giant Cell Arteritis Therapeutics Market Challenges 3.3. PORTER’s Five Forces Analysis 3.4. PESTLE Using Tree Map Analysis 3.5. PESTLE Using Tree Map Analysis 3.5.1. Regulatory Pressures 3.5.2. Aging Populations 3.5.3. Biotech Advancements 3.6. Regulatory Landscape by Region 3.6.1. North America 3.6.2. Europe 3.6.3. Asia Pacific 3.6.4. Middle East and Africa 3.6.5. South America 3.7. Key Opinion Leader Analysis for the Global Industry 3.8. Analysis of Government Schemes and Initiatives for Industry 4. Giant Cell Arteritis Therapeutics Market: Global Market Size and Forecast by Segmentation (by Value in USD Bn) (2024-2032) 4.1. Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 4.1.1. Prednisone 4.1.2. Methotrexate 4.1.3. Tocilizumab 4.1.4. Aspirin 4.2. Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 4.2.1. Haematological disorders 4.2.2. Dermatological disorders 4.2.3. Others 4.3. Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 4.3.1. Corticosteroids 4.3.2. Immunosuppressive Agents 4.3.3. Anticoagulants 4.3.4. Others 4.4. Giant Cell Arteritis Therapeutics Market Size and Forecast, By Region (2024-2032) 4.4.1. North America 4.4.2. Europe 4.4.3. Asia Pacific 4.4.4. Middle East and Africa 4.4.5. South America 5. North America Giant Cell Arteritis Therapeutics Market Size and Forecast by Segmentation (by Value in USD Bn) (2024-2032) 5.1. North America Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 5.1.1. Prednisone 5.1.2. Methotrexate 5.1.3. Tocilizumab 5.1.4. Aspirin 5.2. North America Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 5.2.1. Oral 5.2.2. Intravenous 5.2.3. Subcutaneous 5.2.4. Others 5.3. North America Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 5.3.1. Corticosteroids 5.3.2. Immunosuppressive Agents 5.3.3. Anticoagulants 5.3.4. Others 5.4. North America Giant Cell Arteritis Therapeutics Market Size and Forecast, by Country (2024-2032) 5.4.1. United States 5.4.1.1. United States Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 5.4.1.1.1. Prednisone 5.4.1.1.2. Methotrexate 5.4.1.1.3. Tocilizumab 5.4.1.1.4. Aspirin 5.4.1.2. United States Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 5.4.1.2.1. Oral 5.4.1.2.2. Intravenous 5.4.1.2.3. Subcutaneous 5.4.1.2.4. Others 5.4.1.3. United States Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 5.4.1.3.1. Corticosteroids 5.4.1.3.2. Immunosuppressive Agents 5.4.1.3.3. Anticoagulants 5.4.1.3.4. Others 5.4.2. Canada 5.4.2.1. Canada Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 5.4.2.1.1. Prednisone 5.4.2.1.2. Methotrexate 5.4.2.1.3. Tocilizumab 5.4.2.1.4. Aspirin 5.4.2.2. Canada Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 5.4.2.2.1. Oral 5.4.2.2.2. Intravenous 5.4.2.2.3. Subcutaneous 5.4.2.2.4. Others 5.4.2.3. Canada Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 5.4.2.3.1. Corticosteroids 5.4.2.3.2. Immunosuppressive Agents 5.4.2.3.3. Anticoagulants 5.4.2.3.4. Others 5.4.3. Mexico 5.4.3.1. Mexico Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 5.4.3.1.1. Prednisone 5.4.3.1.2. Methotrexate 5.4.3.1.3. Tocilizumab 5.4.3.1.4. Aspirin 5.4.3.2. Mexico Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 5.4.3.2.1. Oral 5.4.3.2.2. Intravenous 5.4.3.2.3. Subcutaneous 5.4.3.2.4. Others 5.4.3.3. Mexico Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 5.4.3.3.1. Corticosteroids 5.4.3.3.2. Immunosuppressive Agents 5.4.3.3.3. Anticoagulants 5.4.3.3.4. Others 6. Europe Giant Cell Arteritis Therapeutics Market Size and Forecast by Segmentation (by Value in USD Bn) (2024-2032) 6.1. Europe Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 6.2. Europe Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 6.3. Europe Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 6.4. Europe Giant Cell Arteritis Therapeutics Market Size and Forecast, by Country (2024-2032) 6.4.1. United Kingdom 6.4.1.1. United Kingdom Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 6.4.1.2. United Kingdom Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 6.4.1.3. United Kingdom Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 6.4.2. France 6.4.2.1. France Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 6.4.2.2. France Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 6.4.2.3. France Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 6.4.3. Germany 6.4.3.1. Germany Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 6.4.3.2. Germany Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 6.4.3.3. Germany Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 6.4.4. Italy 6.4.4.1. Italy Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 6.4.4.2. Italy Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 6.4.4.3. Italy Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 6.4.5. Spain 6.4.5.1. Spain Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 6.4.5.2. Spain Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 6.4.5.3. Spain Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 6.4.6. Sweden 6.4.6.1. Sweden Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 6.4.6.2. Sweden Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 6.4.6.3. Sweden Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 6.4.7. Russia 6.4.7.1. Russia Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 6.4.7.2. Russia Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 6.4.7.3. Russia Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 6.4.8. Rest of Europe 6.4.8.1. Rest of Europe Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 6.4.8.2. Rest of Europe Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 6.4.8.3. Rest of Europe Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 7. Asia Pacific Giant Cell Arteritis Therapeutics Market Size and Forecast by Segmentation (by Value in USD Bn) (2024-2032) 7.1. Asia Pacific Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 7.2. Asia Pacific Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 7.3. Asia Pacific Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 7.4. Asia Pacific Giant Cell Arteritis Therapeutics Market Size and Forecast, by Country (2024-2032) 7.4.1. China 7.4.1.1. China Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 7.4.1.2. China Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 7.4.1.3. China Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 7.4.2. S Korea 7.4.2.1. S Korea Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 7.4.2.2. S Korea Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 7.4.2.3. S Korea Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 7.4.3. Japan 7.4.3.1. Japan Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 7.4.3.2. Japan Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 7.4.3.3. Japan Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 7.4.4. India 7.4.4.1. India Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 7.4.4.2. India Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 7.4.4.3. India Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 7.4.5. Australia 7.4.5.1. Australia Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 7.4.5.2. Australia Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 7.4.5.3. Australia Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 7.4.6. Indonesia 7.4.6.1. Indonesia Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 7.4.6.2. Indonesia Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 7.4.6.3. Indonesia Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 7.4.7. Malaysia 7.4.7.1. Malaysia Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 7.4.7.2. Malaysia Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 7.4.7.3. Malaysia Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 7.4.8. Philippines 7.4.8.1. Philippines Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 7.4.8.2. Philippines Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 7.4.8.3. Philippines Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 7.4.9. Thailand 7.4.9.1. Thailand Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 7.4.9.2. Thailand Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 7.4.9.3. Thailand Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 7.4.10. Vietnam 7.4.10.1. Vietnam Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 7.4.10.2. Vietnam Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 7.4.10.3. Vietnam Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 7.4.11. Rest of Asia Pacific 7.4.11.1. Rest of Asia Pacific Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 7.4.11.2. Rest of Asia Pacific Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 7.4.11.3. Rest of Asia Pacific Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 8. Middle East and Africa Giant Cell Arteritis Therapeutics Market Size and Forecast (by Value in USD Bn) (2024-2032) 8.1. Middle East and Africa Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 8.2. Middle East and Africa Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 8.3. Middle East and Africa Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 8.4. Middle East and Africa Giant Cell Arteritis Therapeutics Market Size and Forecast, by Country (2024-2032) 8.4.1. South Africa 8.4.1.1. South Africa Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 8.4.1.2. South Africa Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 8.4.1.3. South Africa Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 8.4.2. GCC 8.4.2.1. GCC Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 8.4.2.2. GCC Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 8.4.2.3. GCC Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 8.4.3. Egypt 8.4.3.1. Egypt Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 8.4.3.2. Egypt Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 8.4.3.3. Egypt Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 8.4.4. Nigeria 8.4.4.1. Nigeria Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 8.4.4.2. Nigeria Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 8.4.4.3. Nigeria Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 8.4.5. Rest of ME&A 8.4.5.1. Rest of ME&A Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 8.4.5.2. Rest of ME&A Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 8.4.5.3. Rest of ME&A Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 9. South America Giant Cell Arteritis Therapeutics Market Size and Forecast by Segmentation (by Value in USD Bn) (2024-2032) 9.1. South America Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 9.2. South America Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 9.3. South America Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 9.4. South America Giant Cell Arteritis Therapeutics Market Size and Forecast, by Country (2024-2032) 9.4.1. Brazil 9.4.1.1. Brazil Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 9.4.1.2. Brazil Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 9.4.1.3. Brazil Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 9.4.2. Argentina 9.4.2.1. Argentina Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 9.4.2.2. Argentina Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 9.4.2.3. Argentina Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 9.4.3. Colombia 9.4.3.1. Colombia Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 9.4.3.2. Colombia Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 9.4.3.3. Colombia Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 9.4.4. Chile 9.4.4.1. Chile Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 9.4.4.2. Chile Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 9.4.4.3. Chile Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 9.4.5. Rest Of South America 9.4.5.1. Rest Of South America Giant Cell Arteritis Therapeutics Market Size and Forecast, By Therapeutics (2024-2032) 9.4.5.2. Rest Of South America Giant Cell Arteritis Therapeutics Market Size and Forecast, By Route of Administration (2024-2032) 9.4.5.3. Rest Of South America Giant Cell Arteritis Therapeutics Market Size and Forecast, By Mechanism of Action (2024-2032) 10. Company Profile: Key Players 10.1. Kiniksa Pharmaceuticals, Ltd. 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Recent Developments 10.2. Regeneron 10.3. AbbVie, Inc. 10.4. Bristol-Myers Squibb Company 10.5. Abbott 10.6. Janssen Pharmaceuticals 10.7. Pfizer Inc. 10.8. Eli Lilly and Company 10.9. ChemoCentryx 10.10. GlaxoSmithKline plc 10.11. InflaRx 10.12. Fresenius Kabi Deutschland GmbH 10.13. Sanofi 10.14. AstraZeneca 10.15. F. Hoffmann-La Roche Ltd. 10.16. Novartis AG 10.17. Bio Thera Solutions Ltd. 10.18. Livzon Pharmaceutical Group Inc. 10.19. Hisun Biopharmaceutical Co., Ltd. 10.20. Chugai Pharmaceutical Co., Ltd. 10.21. Dr Reddy’s Laboratories 10.22. Celltrion, Inc. 11. Key Findings 12. Industry Recommendations 13. Giant Cell Arteritis Therapeutics Market: Research Methodology
